FindMyKOL
Clinical trialNCT07261657RecruitingPhase Early 1Interventional

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

NCT07261657 is a phase early 1 interventional trial sponsored by Seth Pollack. As of 21 Nov 2026, it is recruiting participants. It studies Nogapendekin alfa inbakicept in Myxoid Liposarcoma, Round Cell Liposarcoma and 1 more condition. The registry lists an enrollment of 8 participants at 1 site in 1 country. The registry lists a start date of 13 Apr 2026 and a primary completion date of 2 Sept 2030. One of its registered investigators has a FindMyKOL profile.

SponsorSeth Pollack →Enrollment8Myxoid LiposarcomaRound Cell LiposarcomaSynovial Sarcoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07261657
FieldValue
Registry IDNCT07261657
StatusRecruiting
PhasePhase Early 1
Study typeInterventional trial
Lead sponsorSeth Pollack
Enrollment8
Registered sites1
Countries1
ConditionsMyxoid Liposarcoma, Round Cell Liposarcoma and Synovial Sarcoma
DrugsNogapendekin alfa inbakicept
Start13 Apr 2026
Primary completion2 Sept 2030
Study completion2 Sept 2032
Last update posted27 Aug 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This early phase I trial tests the safety and how well N-803 works in treating patients with synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCL) that is growing, spreading, or getting worse (progressive) after being treated with adoptive cellular therapy (ACT) using T-cell receptor therapy (T-CRT). Synovial sarcoma is a rare, slow-growing cancer that affects the soft tissues, like muscles or ligaments near the joints. Myxoid/round cell liposarcoma is a rare type of soft tissue sarcoma cancer that originates from fat cells usually in the arms and legs. N-803 is a type of immunotherapy-a treatment that helps patients' own immune system fight cancer, and it is made up of a natural protein called interleukin-15 (IL-15) that is important for growing and activating immune cells. Studies have shown that patients can progress after initially responding to TCR-T, so this trial will use N-803 to stimulate rare persisting cells (cells that survive treatment and cause treatment failure and disease relapse) to make them work better at attacking the cancer. Adoptive cell therapy is a type of therapy that uses a patient's own immune cells to fight cancer. T-cell receptor therapy is a type of ACT that can recognize better recognize and bind to protein in cancer cells. Giving N-803 may be safe and tolerable in patients with SS or MRCL.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Illinois, United States1 site, 1 recruiting
  • Northwestern University

    Chicago

    Seth M. Pollack, MD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 1 site, 1 recruitingIL1IndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07261657

Each answer restates registry values shown on this page.

What is NCT07261657?

NCT07261657 is a phase early 1 interventional trial sponsored by Seth Pollack. It studies Nogapendekin alfa inbakicept in Myxoid Liposarcoma, Round Cell Liposarcoma and 1 more condition.

Is NCT07261657 recruiting?

As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT07261657?

The registry names Seth M Pollack, MD (principal investigator, Northwestern University) as the overall official.

Where does NCT07261657 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT07261657 study?

The registered drug and biological interventions are Nogapendekin alfa inbakicept.

When is NCT07261657 expected to complete?

The registry lists a primary completion date of 2 Sept 2030 and a study completion date of 2 Sept 2032. The sponsor last updated the record on 27 Aug 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.